Part-Time
Early-stage life science venture investor
$17.71 - $24.94/hr
Beverly, MA, USA
In Person
See people who can refer or advise you
Mass General Brigham Ventures funds early-stage life science ideas arising from Mass General Brigham’s research network. It provides first access to deal flow and proprietary rights, backing the formation and growth of new companies and technologies. It uses capital and support to help translate bold innovations into drugs and medical technologies that improve patient outcomes worldwide.
Company Size
1-10
Company Stage
N/A
Total Funding
$1.9B
Headquarters
Cambridge, Massachusetts
Founded
2008
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Flexible Work Hours
Remote Work Options
Hybrid Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Family Planning Benefits
Fertility Treatment Support
Professional Development Budget
Conference Attendance Budget
Wellness Program
Mental Health Support
Gym Membership
Phone/Internet Stipend
Home Office Stipend
Stock Options
Company Equity
401(k) Company Match
Parental Leave
Adoption Assistance
Childcare Support
Relocation Assistance
Employee Referral Bonus
Tuition Reimbursement
Professional Certification Support
Mentorship Program
Meal Benefits
Commuter Benefits
Legal Services
Employee Discounts
Company Social Events
Latest Press Releases from Claris Bio.
InStride Health, a provider of virtual specialty mental healthcare for children and young adults, has raised $30 million in Series C funding led by Echo Health Ventures and FMZ Ventures. Existing investors including .406 Ventures, General Catalyst and Mass General Brigham Ventures also participated. Founded in 2021, InStride offers insurance-based treatment for anxiety and obsessive-compulsive disorder in patients aged seven to 24. The company pairs each patient with a care team comprising a psychiatrist, therapist and exposure coach, providing support through text and a mobile application. InStride has treated 5,000 patients across 17 states, primarily on the East Coast and Texas. The company published data showing 97% of patients demonstrated clinical improvement, with a 53% average reduction in anxiety scores. The funding will support expansion into new markets and strengthen payer partnerships.
Violet Therapeutics, a biotechnology company developing therapies for neurodegenerative diseases, has raised $4.75 million in a seed extension round led by Lifespan Vision Ventures. Dementia Discovery Fund, UTEC, Ono Venture Investment and Mass General Brigham Ventures also participated. The Cambridge-based company will use the funding to advance its lead small molecule programme targeting EphB3 through IND-enabling activities. The therapy aims to halt and potentially reverse cognitive decline through glial-mediated synaptic preservation, addressing synaptic loss, the strongest predictor of cognitive decline in Alzheimer's and other neurodegenerative diseases. Violet's proprietary CONNECT platform maps cell-cell interaction networks to identify novel therapeutic targets. Founded by Mass General Brigham Ventures with researchers from Brigham and Women's Hospital, the company is developing first-in-class CNS therapies.
Registered nurses at Brigham and Women's Hospital will hold an informational picket on 29 April, protesting Mass General Brigham's corporate decisions affecting patient care and workforce conditions. The Massachusetts Nurses Association represents the nurses, who will demonstrate from 14:00 to 16:00 outside the hospital at 75 Francis Street, Boston. Nurses cite several service closures under MGB, including the Weiner Centre, Burn Unit and Integrated Care Management Programme. They criticise the health system's bargaining proposals, particularly a 0% wage offer for nurses below top step, whilst MGB reported a $59.2 million operating gain in 2025 and paid its top 14 executives $35.9 million in fiscal year 2024. The informational picket will not disrupt patient care, with nurses participating outside working hours.
Approximately 450 clinicians at Mass General Brigham Home Care, represented by the Massachusetts Nurses Association, will hold an informational picket on 24 March outside Massachusetts General Hospital. The clinicians are seeking their first union contract after more than 20 bargaining sessions since March 2025. The bargaining unit includes registered nurses, occupational therapists, physical therapists, speech language pathologists, social workers and dieticians who voted to join the MNA in June 2024. They are demanding reasonable caseload limits, clear productivity standards, competitive wages and recruitment protections. MGB reported a $59.2 million operating gain in the year ending September 2025, with CEO Dr Anne Klibanski's compensation rising 40% to $8.4 million in 2024. The picket is scheduled for 15:30 to 17:00 and is not a strike.